Key eligibility criteria included EGFR and ALK clinically actionable mutation-negative, immune checkpoint inhibitor-naive and chemotherapy-naive metastatic NSCLC with a PD-L1 expression level of ≥1% (Methods). This evidence concerns the gene CD274 and non-small cell lung carcinoma.